Gradalis

The drug combines an RNAi payload with an agent designed to stimulate a patient's immune system against their tumors.

Title: Nucleic Acid Microparticles for Pulmonary Delivery
Patent Number: 8,808,747
Filed: April 17, 2008

Key RNAi Drugs in the Clinic

Premium

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

Gradalis has promoted Phillip Maples as executive vice president and chief technical officer.

Following the close of Dicerna Pharmaceuticals Series C round of financing last week, the RNAi therapeutics space has seen a dramatic increase in investor interest, with privately held companies in the field pulling in more than $100 million thus far in 2013.

Gradalis has named Joseph Limber as its president and CEO, replacing David Shanahan, who was a co-founder of the company.

Gradalis this week announced interim data from a phase II trial of its personalized cancer vaccine, dubbed FANG, showing that the therapy elicits an immune response and delays time to disease recurrence in advanced-stage ovarian patients by more than a year compared with those re

Gradalis announced this week that it has closed a $24 million Series B round of financing.

Two years after the US Patent and Trademark Office reinstated its core patent, Australia's Benitec Biopharma has once again set its sights on finding licensees for its expressed RNAi intellectual property.

With its core expressed RNAi technology under evaluation in several phase I and II cancer studies, Gradalis is setting its sights on transitioning from a company focused on a handful of drug candidates into one with a platform technology that can be partnered out to others workin

Pages

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.